Expertise in
1
conditions

Manik S. Chatterjee

Wuerzburg, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Wuerzburg, BY, DE 

Overview

Manik Chatterjee practices practicing medicine in Wuerzburg, Germany.

Mr. Chatterjee is highly rated in 1 condition, according to our data. His clinical expertise encompasses Multiple Myeloma, Leukemia, Melanoma, and Neurotoxicity Syndromes.

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Wuerzburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
View 1 Less Clinical Trial

50 Total Publications

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.
VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.
Journal: Scientific reports
Published: October 23, 2025

Frequently Asked Questions about Manik S. Chatterjee

Is Manik S. Chatterjee a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Manik S. Chatterjee is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Manik S. Chatterjee participate in research or clinical trials?

Yes. Manik S. Chatterjee has published 50 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Manik S. Chatterjee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chatterjee's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile